Alex Goldberg

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) and Cytokinetics, Incorporated (NASDAQ:CYTK) Added to Equity Profile Report's NASDAQ Gainers Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 06/19/2013 -- Equity Profile Report expands its NASDAQ Active Stock Weekly Watch List adding Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) and Cytokinetics, Incorporated (NASDAQ:CYTK).

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) a biopharmaceutical company that focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States closed up in its previous session (+7.57%) on 9,269,689 shares traded. Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) is currently up (+405.95%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)

Cytokinetics, Incorporated (NASDAQ:CYTK) a clinical-stage biopharmaceutical company that focuses on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions closed down in its previous session (-3.70%) on 11,237,295 shares traded after CYTOKINETICS INC Filed SEC form 8-K, Other Events. Cytokinetics, Incorporated (NASDAQ:CYTK) is currently down (-10.84%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Cytokinetics, Incorporated (NASDAQ:CYTK)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com